Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Intensity modulated radiotherapy in locally advanced thyroid cancer: Outcomes of a sequential phase I dose-escalation study.

Rooney KP, Miah AB, Bhide SA, Guerrero-Urbano MT, Sharabiani MT, Newbold KL, Grove L, Harrington KJ, Nutting CM.

Radiother Oncol. 2018 Apr;127(1):43-48. doi: 10.1016/j.radonc.2018.02.002. Epub 2018 Mar 7.

PMID:
29525412
2.

MRI-based Assessment of 3D Intrafractional Motion of Head and Neck Cancer for Radiation Therapy.

Gurney-Champion OJ, McQuaid D, Dunlop A, Wong KH, Welsh LC, Riddell AM, Koh DM, Oelfke U, Leach MO, Nutting CM, Bhide SA, Harrington KJ, Panek R, Newbold KL.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):306-316. doi: 10.1016/j.ijrobp.2017.10.016. Epub 2017 Oct 16.

3.

Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer.

Wong KH, Panek R, Dunlop A, Mcquaid D, Riddell A, Welsh LC, Murray I, Koh DM, Leach MO, Bhide SA, Nutting CM, Oyen WJ, Harrington KJ, Newbold KL.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):759-767. doi: 10.1007/s00259-017-3890-2. Epub 2017 Nov 21.

4.

Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI.

Panek R, Welsh L, Baker LCJ, Schmidt MA, Wong KH, Riddell AM, Koh DM, Dunlop A, Mcquaid D, d'Arcy JA, Bhide SA, Harrington KJ, Nutting CM, Hopkinson G, Richardson C, Box C, Eccles SA, Leach MO, Robinson SP, Newbold KL.

Clin Cancer Res. 2017 Aug 1;23(15):4233-4241. doi: 10.1158/1078-0432.CCR-16-1209. Epub 2017 Mar 17.

5.

The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist's perspective.

Wong KH, Panek R, Bhide SA, Nutting CM, Harrington KJ, Newbold KL.

Br J Radiol. 2017 Mar;90(1071):20160768. doi: 10.1259/bjr.20160768. Review.

6.

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.

McLaughlin M, Barker HE, Khan AA, Pedersen M, Dillon M, Mansfield DC, Patel R, Kyula JN, Bhide SA, Newbold KL, Nutting CM, Harrington KJ.

BMC Cancer. 2017 Jan 31;17(1):86. doi: 10.1186/s12885-017-3084-0.

7.

Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.

Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, Nutting CM, McLaughlin M, Harrington KJ.

Mol Cancer Ther. 2017 Jan;16(1):25-34. doi: 10.1158/1535-7163.MCT-16-0239. Epub 2016 Nov 9.

8.

Normal Tissue Complication Probability (NTCP) Modelling of Severe Acute Mucositis using a Novel Oral Mucosal Surface Organ at Risk.

Dean JA, Welsh LC, Wong KH, Aleksic A, Dunne E, Islam MR, Patel A, Patel P, Petkar I, Phillips I, Sham J, Schick U, Newbold KL, Bhide SA, Harrington KJ, Nutting CM, Gulliford SL.

Clin Oncol (R Coll Radiol). 2017 Apr;29(4):263-273. doi: 10.1016/j.clon.2016.12.001. Epub 2017 Jan 3.

9.

Time-resolved angiography with stochastic trajectories for dynamic contrast-enhanced MRI in head and neck cancer: Are pharmacokinetic parameters affected?

Panek R, Schmidt MA, Borri M, Koh DM, Riddell A, Welsh L, Dunlop A, Powell C, Bhide SA, Nutting CM, Harrington KJ, Newbold KL, Leach MO.

Med Phys. 2016 Nov;43(11):6024.

PMID:
27806585
10.

Functional Data Analysis Applied to Modeling of Severe Acute Mucositis and Dysphagia Resulting From Head and Neck Radiation Therapy.

Dean JA, Wong KH, Gay H, Welsh LC, Jones AB, Schick U, Oh JH, Apte A, Newbold KL, Bhide SA, Harrington KJ, Deasy JO, Nutting CM, Gulliford SL.

Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):820-831. doi: 10.1016/j.ijrobp.2016.08.013. Epub 2016 Aug 22.

11.

DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.

Petkar I, Rooney K, Roe JW, Patterson JM, Bernstein D, Tyler JM, Emson MA, Morden JP, Mertens K, Miles E, Beasley M, Roques T, Bhide SA, Newbold KL, Harrington KJ, Hall E, Nutting CM.

BMC Cancer. 2016 Oct 6;16(1):770.

12.

Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma.

Bhide SA, Thway K, Lee J, Wong K, Clarke P, Newbold KL, Nutting CM, Harrington KJ.

Br J Cancer. 2016 Sep 27;115(7):825-30. doi: 10.1038/bjc.2016.266. Epub 2016 Sep 1.

13.

A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer.

Wong KH, Kuciejewska A, Sharabiani MTA, Ng-Cheng-Hin B, Hoy S, Hurley T, Rydon J, Grove L, Santos A, Ryugenji M, Bhide SA, Nutting CM, Harrington KJ, Newbold KL.

Radiother Oncol. 2017 Feb;122(2):207-211. doi: 10.1016/j.radonc.2016.06.015. Epub 2016 Jul 5.

PMID:
27393218
14.

Evaluation of radiotherapy techniques for radical treatment of lateralised oropharyngeal cancers : Dosimetry and NTCP.

McQuaid D, Dunlop A, Nill S, Franzese C, Nutting CM, Harrington KJ, Newbold KL, Bhide SA.

Strahlenther Onkol. 2016 Aug;192(8):516-25. doi: 10.1007/s00066-016-0980-1. Epub 2016 Jun 13.

PMID:
27295511
15.

Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy.

Dean JA, Wong KH, Welsh LC, Jones AB, Schick U, Newbold KL, Bhide SA, Harrington KJ, Nutting CM, Gulliford SL.

Radiother Oncol. 2016 Jul;120(1):21-7. doi: 10.1016/j.radonc.2016.05.015. Epub 2016 May 27.

16.

Total Mucosal Irradiation with Intensity-modulated Radiotherapy in Patients with Head and Neck Carcinoma of Unknown Primary: A Pooled Analysis of Two Prospective Studies.

Richards TM, Bhide SA, Miah AB, Del Rosario L, Bodla S, Thway K, Gujral DM, Rooney KP, Schick U, McGovern T, Grove L, Newbold KL, Harrington KJ, Nutting CM.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e77-84. doi: 10.1016/j.clon.2016.04.035. Epub 2016 May 11.

17.

Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.

Miah AB, Gulliford SL, Morden J, Newbold KL, Bhide SA, Zaidi SH, Hall E, Harrington KJ, Nutting CM.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e69-76. doi: 10.1016/j.clon.2016.02.009. Epub 2016 Mar 17.

18.

Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk.

Dean JA, Welsh LC, McQuaid D, Wong KH, Aleksic A, Dunne E, Islam MR, Patel A, Patel P, Petkar I, Phillips I, Sham J, Newbold KL, Bhide SA, Harrington KJ, Gulliford SL, Nutting CM.

Radiother Oncol. 2016 Apr;119(1):166-71. doi: 10.1016/j.radonc.2016.02.022. Epub 2016 Mar 9.

19.

Induction Chemotherapy Followed by Chemo-intensity-modulated Radiotherapy for Locally Advanced Nasopharyngeal Cancer.

Miah AB, Bhide SA, Del Rosario L, Matthews J, Nicol R, Tanay MA, Gupta S, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM.

Clin Oncol (R Coll Radiol). 2016 Aug;28(8):e61-7. doi: 10.1016/j.clon.2016.01.012. Epub 2016 Feb 11.

PMID:
26876458
20.

Repeatability and sensitivity of T2* measurements in patients with head and neck squamous cell carcinoma at 3T.

Panek R, Welsh L, Dunlop A, Wong KH, Riddell AM, Koh DM, Schmidt MA, Doran S, Mcquaid D, Hopkinson G, Richardson C, Nutting CM, Bhide SA, Harrington KJ, Robinson SP, Newbold KL, Leach MO.

J Magn Reson Imaging. 2016 Jul;44(1):72-80. doi: 10.1002/jmri.25134. Epub 2016 Jan 22.

21.

Characterizing Heterogeneity within Head and Neck Lesions Using Cluster Analysis of Multi-Parametric MRI Data.

Borri M, Schmidt MA, Powell C, Koh DM, Riddell AM, Partridge M, Bhide SA, Nutting CM, Harrington KJ, Newbold KL, Leach MO.

PLoS One. 2015 Sep 23;10(9):e0138545. doi: 10.1371/journal.pone.0138545. eCollection 2015.

22.

A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes.

Miah AB, Schick U, Bhide SA, Guerrero-Urbano MT, Clark CH, Bidmead AM, Bodla S, Del Rosario L, Thway K, Wilson P, Newbold KL, Harrington KJ, Nutting CM.

Br J Cancer. 2015 Jan 6;112(1):32-8. doi: 10.1038/bjc.2014.553. Epub 2014 Dec 4.

23.

Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers.

Gujral DM, Miah AB, Bodla S, Richards TM, Welsh L, Schick U, Powell CJ, Clark CH, Bidmead MA, Grove L, Guerrero-Urbano T, Bhide SA, Newbold KL, Harrington KJ, Nutting CM.

Oral Oncol. 2014 Nov;50(11):1089-97. doi: 10.1016/j.oraloncology.2014.07.018. Epub 2014 Sep 6.

PMID:
25200524
24.

Neurocognitive function after (chemo)-radiotherapy for head and neck cancer.

Welsh LC, Dunlop AW, McGovern T, McQuaid D, Dean JA, Gulliford SL, Bhide SA, Harrington KJ, Nutting CM, Newbold KL.

Clin Oncol (R Coll Radiol). 2014 Dec;26(12):765-75. doi: 10.1016/j.clon.2014.06.014. Epub 2014 Jul 11. Review.

PMID:
25028338
25.

Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: a survey of centres participating in a national randomised controlled trial.

Gujral DM, Piercy D, Morden JP, Emson M, Hall E, Miah AB, Bhide SA, Newbold KL, Harrington KJ, Nutting CM.

Oral Oncol. 2014 Feb;50(2):141-6. doi: 10.1016/j.oraloncology.2013.10.012. Epub 2013 Nov 18.

PMID:
24263110
26.

Dose-response analysis of parotid gland function: what is the best measure of xerostomia?

Miah AB, Gulliford SL, Clark CH, Bhide SA, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM.

Radiother Oncol. 2013 Mar;106(3):341-5. doi: 10.1016/j.radonc.2013.03.009. Epub 2013 Apr 6.

PMID:
23566529
27.

The effect of concomitant chemotherapy on parotid gland function following head and neck IMRT.

Miah AB, Gulliford SL, Bhide SA, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM.

Radiother Oncol. 2013 Mar;106(3):346-51. doi: 10.1016/j.radonc.2013.03.006. Epub 2013 Mar 26.

PMID:
23540553
28.

Equivalence of cisplatin and carboplatin-based chemoradiation for locally advanced squamous cell carcinoma of the head and neck: a matched-pair analysis.

Wilkins AC, Rosenfelder N, Schick U, Gupta S, Thway K, Nutting CM, Harrington KJ, Newbold K, Bhide SA.

Oral Oncol. 2013 Jun;49(6):615-9. doi: 10.1016/j.oraloncology.2013.02.004. Epub 2013 Feb 26.

PMID:
23485743
29.

Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer.

Powell C, Schmidt M, Borri M, Koh DM, Partridge M, Riddell A, Cook G, Bhide SA, Nutting CM, Harrington KJ, Newbold KL.

Radiother Oncol. 2013 Jan;106(1):112-7. doi: 10.1016/j.radonc.2012.09.009. Epub 2012 Oct 22.

PMID:
23089306
30.

Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers.

Bhide SA, Newbold KL, Harrington KJ, Nutting CM.

Br J Radiol. 2012 May;85(1013):487-94. doi: 10.1259/bjr/85942136. Review.

31.

The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.

Zaidi S, McLaughlin M, Bhide SA, Eccles SA, Workman P, Nutting CM, Huddart RA, Harrington KJ.

PLoS One. 2012;7(4):e35436. doi: 10.1371/journal.pone.0035436. Epub 2012 Apr 16.

32.

The role of intensity modulated radiotherapy in advanced oral cavity carcinoma.

Bhide SA, Ahmed M, Newbold K, Harrington KJ, Nutting CM.

J Cancer Res Ther. 2012 Jan;8 Suppl 1:S67-71. doi: 10.4103/0973-1482.92218. Review.

PMID:
22322735
33.

Dose-response analysis of acute oral mucositis and pharyngeal dysphagia in patients receiving induction chemotherapy followed by concomitant chemo-IMRT for head and neck cancer.

Bhide SA, Gulliford S, Schick U, Miah A, Zaidi S, Newbold K, Nutting CM, Harrington KJ.

Radiother Oncol. 2012 Apr;103(1):88-91. doi: 10.1016/j.radonc.2011.12.027. Epub 2012 Jan 24.

PMID:
22280809
34.

An exploratory study of the influence of clinico-demographic variables on swallowing and swallowing-related quality of life in a cohort of oral and oropharyngeal cancer patients treated with primary surgery.

Dwivedi RC, Chisholm EJ, Khan AS, Harris NJ, Bhide SA, St Rose S, Kerawala CJ, Clarke PM, Nutting CM, Rhys-Evans PH, Harrington KJ, Kazi R.

Eur Arch Otorhinolaryngol. 2012 Apr;269(4):1233-9. doi: 10.1007/s00405-011-1756-y. Epub 2011 Sep 10.

PMID:
21909656
35.

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A'Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group.

Lancet Oncol. 2011 Feb;12(2):127-36. doi: 10.1016/S1470-2045(10)70290-4. Epub 2011 Jan 12.

36.

Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.

Miah AB, Bhide SA, Guerrero-Urbano MT, Clark C, Bidmead AM, St Rose S, Barbachano Y, A'hern R, Tanay M, Hickey J, Nicol R, Newbold KL, Harrington KJ, Nutting CM.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):539-47. doi: 10.1016/j.ijrobp.2010.09.055. Epub 2011 Jan 13.

PMID:
21236602
37.

Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy.

Bhide SA, Gulliford S, Fowler J, Rosenfelder N, Newbold K, Harrington KJ, Nutting CM.

Radiother Oncol. 2010 Oct;97(1):86-91. doi: 10.1016/j.radonc.2010.08.013. Epub 2010 Sep 7.

PMID:
20826031
38.

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, Renouf LC, Thway K, Sibtain A, McNeish IA, Newbold KL, Goldsweig H, Coffin R, Nutting CM.

Clin Cancer Res. 2010 Aug 1;16(15):4005-15. doi: 10.1158/1078-0432.CCR-10-0196.

39.

Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair.

Hingorani M, White CL, Zaidi S, Pandha HS, Melcher AA, Bhide SA, Nutting CM, Syrigos KN, Vile RG, Vassaux G, Harrington KJ.

Mol Ther. 2010 Sep;18(9):1599-605. doi: 10.1038/mt.2010.120. Epub 2010 Jun 29.

40.

The role of intensity-modulated radiotherapy in head and neck cancer.

Bhide SA, Kazi R, Newbold K, Harrington KJ, Nutting CM.

Indian J Cancer. 2010 Jul-Sep;47(3):267-73. doi: 10.4103/0019-509X.64719. Review.

41.

Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents.

Harrington KJ, Kazi R, Bhide SA, Newbold K, Nutting CM.

Indian J Cancer. 2010 Jul-Sep;47(3):248-59. doi: 10.4103/0019-509X.64711. Review.

42.

External beam radiotherapy for differentiated thyroid cancer.

Powell C, Newbold K, Harrington KJ, Bhide SA, Nutting CM.

Clin Oncol (R Coll Radiol). 2010 Aug;22(6):456-63. doi: 10.1016/j.clon.2010.03.012. Epub 2010 Apr 27. Review.

PMID:
20427166
43.

Recent advances in radiotherapy.

Bhide SA, Nutting CM.

BMC Med. 2010 Apr 28;8:25. doi: 10.1186/1741-7015-8-25. Review.

44.

Advances in radiotherapy for head and neck cancer.

Bhide SA, Nutting CM.

Oral Oncol. 2010 Jun;46(6):439-41. doi: 10.1016/j.oraloncology.2010.03.005. Epub 2010 Apr 20. Review.

PMID:
20409746
45.

Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers.

Powell C, Mikropoulos C, Kaye SB, Nutting CM, Bhide SA, Newbold K, Harrington KJ.

Cancer Treat Rev. 2010 Nov;36(7):566-75. doi: 10.1016/j.ctrv.2010.03.003. Epub 2010 Apr 20. Review.

PMID:
20409643
46.

Advances in chemotherapy for head and neck cancer.

Bhide SA, Nutting CM.

Oral Oncol. 2010 Jun;46(6):436-8. doi: 10.1016/j.oraloncology.2010.03.004. Epub 2010 Apr 18. Review.

PMID:
20400360
47.

Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study.

Bhide SA, Davies M, Burke K, McNair HA, Hansen V, Barbachano Y, El-Hariry IA, Newbold K, Harrington KJ, Nutting CM.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1360-8. doi: 10.1016/j.ijrobp.2009.04.005.

PMID:
20338474
48.

Combined chemotherapy and intensity-modulated radiotherapy for the treatment of head and neck cancers.

Bhide SA, Newbold KL, Harrington KJ, Nutting CM.

Expert Rev Anticancer Ther. 2010 Mar;10(3):297-300. doi: 10.1586/era.10.15. No abstract available.

PMID:
20214509
49.

Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer.

Bhide SA, Gulliford S, Kazi R, El-Hariry I, Newbold K, Harrington KJ, Nutting CM.

Radiother Oncol. 2009 Dec;93(3):539-44. doi: 10.1016/j.radonc.2009.09.017. Epub 2009 Oct 31.

PMID:
19883951
50.

Radiation-induced xerostomia: pathophysiology, prevention and treatment.

Bhide SA, Miah AB, Harrington KJ, Newbold KL, Nutting CM.

Clin Oncol (R Coll Radiol). 2009 Dec;21(10):737-44. doi: 10.1016/j.clon.2009.09.002. Epub 2009 Oct 14. Review.

PMID:
19833490

Supplemental Content

Loading ...
Support Center